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Abstract
Liver fibrosis, and its end stage cirrhosis are a major cause of morbidity and mortality and therapeutic options are
limited. However, the traditional view of liver disease as an irreversible process is obsolete and it is now evident
that the development of liver fibrosis is a dynamic and potentially bidirectional process. Spontaneous resolution of
scarring is seen in animal models of liver fibrosis and in human trials in which the stimuli responsible for chronic or
repeated hepatic inflammation is successfully removed. Key players in the process are hepatic stellate cells,
macrophages, MMPs and their inhibitors Timps. It is also evident that in advanced fibrotic liver disease, specific
histological features define what is currently described as “irreversible” fibrosis. This includes the development of
paucicellular scars enriched in extensively cross-linked matrix components, such as fibrillar collagen and elastin. Our
recent work has focused on the role of macrophage metalloelastase (MMP-12) in the turnover of elastin in
reversible and irreversible models of fibrosis. We have shown that elastin turnover in liver injury and fibrosis is
regulated by macrophages via Mmp-12 expression, activity and ratio to its inhibitor Timp-1. Failure of elastin
degradation, together with increased deposition leads to accumulation of elastin in the fibrotic scars.
Introduction
The complications of liver fibrosis represent a major
health burden to our society. World-wide, chronic viral
hepatitis is the predominant cause of liver fibrosis, whereas
in the Western Hemisphere alcoholic liver disease, chronic
viral hepatitis and increasingly non-alcoholic fatty liver
disease are the main causes. Furthermore the prevalence
of liver cirrhosis in the UK has increased dramatically in
the past two decades [1] and it is now the fifth cause of
death . Liver fibrosis and its end-stage, cirrhosis, result
from a sustained wound healing response to chronic or
repeated injury, leading to formation of scar tissue, loss of
tissue architecture and organ failure. Regardless if the
initial cause of injury, fibrosis represents the final common
pathway of chronic hepatic inflammation. However, the
wound healing response is a dynamic process and has the
potential to resolve without scarring. Removal of the injury
stimulus has been shown to improve liver fibrosis in alco-
holic liver disease [2], viral hepatitis [3-5], biliary obstruc-
tion [6] and autoimmune hepatitis [7]. Current treatments
for liver fibrosis are directed towards suppression or
removal of inflammatory stimuli that drives the develop-
ment of fibrosis. However for severe end-stage liver dis-
ease, orthotopic liver transplantation is the only effective
treatment but the availability, suitability and long-term
effectiveness of liver transplantation severely restrict it uti-
lity as therapy.
Experimental models have confirmed the possibility of
reversion of established liver fibrosis [8-10]. Rats injured
with carbon tetrachloride for 4 to 8 weeks develop fibrosis,
but after cessation of the injury are able to revert to vir-
tually normal morphology. On the other hand, when the
injury is protracted for longer time, (12 weeks) cirrhosis
develops and in the absence of ongoing injury there is
only partial reversal with remodelling of a micro-nodular
to a macro-nodular architecture [10]. It is therefore appar-
ent that liver cirrhosis is not simply an extended form of
liver fibrosis, but is associated with particular architectural
and biochemical features that may limit the potential for
resolution.
One of the first events in liver fibrosis is the activation
of resident innate inflammatory cells and the recruitment
of additional inflammatory cells. These include recruited
monocytes/macrophages, with further contributions
from other cell lineages in specific disease states. Many
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tocytes, cholangiocytes, endothelial and inflammatory
cells. The activation of hepatic myofibroblasts, including
hepatic stellate cells (HSCs) is a critical step in the inter-
linked processes of tissue injury and regeneration. HSCs
normally reside in the perisinusoidal space where their
principal function is the storage of retinoids [11,12]. Fol-
lowing liver injury HSCs become activated (transdiffer-
entiate) into contractile and proliferative myofibroblasts
that are responsible for secreting much of the ECM that
characterises liver fibrosis. In early fibrosis there is accu-
mulation of fibronectin and collagen types III and IV
[13]. As liver fibrosis progresses, the ECM accumulates
increasing amounts of types I and type IV fibrillar col-
lagens, addition of other matrix components including
elastin. Both increased matrix deposition and reduction
in matrix degradation concur in the accumulation of the
fibrotic scar [8]. Activated HSCs up-regulate the expres-
sion of potent inhibitors of metalloproteinases (TIMPs)
[14]. Consequently the balance between the action of
matrix-degrading metalloproteinases (MMPs) and their
inhibitors is shifted, facilitating matrix accumulation.
Similarly, the resolution of liver fibrosis is accompanied
by HSC apoptosis, which simultaneously removes both
an important source of ECM deposition and MMP inhi-
bition [15]. Importantly, there is a close anatomical cor-
relation between the site of initial injury and the
subsequent deposition of ECM. However, as fibrosis pro-
gresses bridging fibrosis develops, resulting in formation
of the fibrous septae and regenerative nodules that char-
acterise cirrhosis. What are the features of cirrhosis that
prevent successful remodelling? In animal models of cir-
rhosis, MMPs are present but their action is inhibited by
high levels of TIMP-1 and to a lesser extent TIMP-2
[8-10]. Interestingly, in a rat CCl4 model, TIMP-1 over-
espressing rat develop the same level of fibrosis as wild
type, but are unable to resolve after removal of the injury.
In addition, in these animals hepatic stellate cell apopto-
sis is decreased [16]. In our rodent model, while more
recently deposited septae are readily degraded, the older
septae appear more resistant to degradation [10]. These
pauci-cellular scars are particularly rich in elastin and
cross-links that may render them more resistant to
MMP-mediated degradation.
We have recently shown that the accumulation of elas-
tin is, rather than being only the result of excessive secre-
tion, also results from a failure of elastin degradation
[37]. In a rat model of fibrosis, both tropoelastin and
macrophage metallo-elastase (MMP-12) are increased in
active fibrosis. Elastin is strongly expressed from the
onset of injury but, in contrast to collagen I, only accu-
mulates late, suggesting that degradation occurs during
the early phases of injury. On the other hand a higher
TIMP-1/Mmp-12 ratio is observed in early vs established
fibrosis. In addition, Mmp-12 knock-out mice have both
increased collagen and elastin deposition in a TAA
model of cirrhosis. Current studies are aimed to evaluate
the reversibility of fibrosis in this model.
The role of the ECM in promoting HSC survival should
not be understated. Cell matrix components including col-
lagen-1 [17] and interactions mediated through integrins
[18,19] and discoidin domain receptors [20] can promote
HSC activation and promote HSC survival. Furthermore,
there is increasing evidence that the altered mechanical
properties of fibrotic ECM may directly facilitate myofi-
broblast activation, proliferation and survival through
mechanotransduction responses consequent to enhanced
cytoskeletal tension of cells exposed to stiff fibrotic
matrices [21-24]. In addition, cellular responses to
increased liver stiffness in acute inflammation (oedema)
may represent a conserved mechanism linking acute liver
injury to wound healing and regeneration [25,26].
Resident and recruited inflammatory cells have complex
effects on both the development of fibrosis and its subse-
quent resolution [27]. Prominent amongst these are
recruited monocytes/macrophages and the liver-resident
Kupffer cells. Macrophages have long been regarded as
leading protagonists in the development of tissue fibrosis.
The inhibition of macrophage migration by adenoviral
over-expression of a dominant-negative form of macro-
phage chemotactic protein-1 (MCP-1) has been shown to
reduce macrophage influx and ameliorate fibrosis in a
rodent model of liver fibrosis [28]. However, it has subse-
quently been demonstrated that macrophages have dis-
tinct roles in the injury and recovery phases of liver
fibrosis [29]. This was achieved in experiments with a
transgenic mouse (CD11b-DTR) in which macrophages
could be selectively depleted during both the injury and
recovery phases that follow carbon tetrachloride adminis-
tration in mice. Macrophage depletion at the time of
injury resulted in reduction in both scarring and myofibro-
blast numbers. In contrast, macrophage depletion during
recovery from fibrosis led to a reduction in scar resolution.
This suggested that distinct subpopulations of macro-
phages have discrete functions in the injury and recovery
phases of liver fibrosis.
Macrophages are known to be an important source of
pro-fibrotic chemokines. Macrophage-conditioned media
has been shown to promote HSC activation in vitro. This
effect is mediated by transforming growth factor-beta
(TGFb) and the induction of platelet-derived-growth-factor
(PDGF) receptors on HSCs [30]. Conversely, macrophages
may promote HSC apoptosis during the resolution of liver
fibrosis through expression of HSC death ligands, including
TNFa-related apoptosis-inducing ligand (TRAIL) and
MMP-9 [18,31,32]. Macrophages also appear to function
more directly in matrix remodelling through production of
macrophage-derived metalloproteinases, including MMP-9
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been shown to be the principal source of MMP-13 in a
rodent model of liver fibrosis [35]. Furthermore MMP-13
expression is restricted to regions of liver fibrosis rich in
scar-associated macrophages. This has important implica-
tions in relation to the failure of ECM-degradation in the
paucicellular elastin-rich scars that characterise advanced
cirrhosis. Could macrophages or stem cell technology be
harnessed to seed the hepatic scar with cells that may facil-
itate successful remodelling? The results of provisional
experiments are certainly encouraging.
The role of other cells of the innate and adaptive
immune system in the development of liver fibrosis is less
well defined and has been reviewed in detail elsewhere
[27]. Recent years have seen renewed interest in the role
of natural killer (NK) cells in the resolution of liver fibro-
sis. NK cells have been shown to facilitate HSC deletion in
liver fibrosis [36]. NK cell activation with polyinosinic-
polycytidylic acid or interferon-gamma has been shown to
induce cell death in activated stellate cells and reduce the
severity of scarring in two murine models of liver fibrosis.
Activated HSCs express high levels of retinoic acid early
inducible-1, a ligand for the NKG2D receptor found on
NK cells. It was demonstrated that the enhanced cytotoxi-
city of NK cells against activated HSCs was a consequence
of up-regulation of both the NKG2D receptor and the
TRAIL death ligand. An important implication of this
study is that the manipulation of NK cells might represent
a practical therapeutic strategy to facilitate HSC deletion
in liver fibrosis.
Discussion
Current evidence indicates that the development of liver
fibrosis is a dynamic and potentially bidirectional process.
Spontaneous resolution of scarring is readily seen in ani-
mal models of liver fibrosis and in human trials in which
the stimuli responsible for chronic or repeated hepatic
inflammation is successfully removed. However, it is also
evident that in advanced fibrotic liver disease, specific his-
tological features define what our group has described as
“irreversible” fibrosis. This includes the development of
paucicellular scars enriched in extensively cross-linked
elastin and fibrillar collagen. In the decades to come a key
priority must be the development of strategies to facilitate
the repopulation and effective remodelling of areas of
advanced scarring. It is likely that this will require a com-
bination of cellular therapies and the development of
pharmaceutical agents addressing multiple targets in path-
ways involved in fibrogenesis.
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